We monitor the scientists, clinical trials, and biotech programs working toward a durable cure. We verify the evidence, explain what it actually means, and tell you what's still unproven — in plain English, with the denominators included.
Endogenous insulin production, or a biological replacement sufficient for control — not "reduced use."
Reliable control that lasts — not a short-lived signal or an isolated lab result.
Safety and quality of life are part of the finish line, not an asterisk on it.
A band (how it ranks) and an evidence tier (how proven it is) — always shown together, never a rank alone. This is a preview of 4 programs — see the full leaderboard of all 11 tracked programs, or the methodology here.
One patient, zero immunosuppression, insulin production still detectable past 14 months. First human proof the hardest unsolved piece — immune evasion — can work at all.
Full Trial Report Card →10 of 12 full-dose participants insulin-independent at one year. The strongest human efficacy evidence tracked so far — still requires standard immunosuppression.
Full Trial Report Card →No human trial yet — designed to solve both unsolved problems, cell replacement and immune evasion, at once. IND targeted Q4 2026.
Full Trial Report Card →12 of 12 donor-islet recipients insulin-independent in a UChicago Medicine pilot. Small and uncontrolled, but a real near-term benefit for people on transplant waitlists today.
Full Trial Report Card →Every claim is checked against ClinicalTrials.gov, FDA filings, peer-reviewed journals, and company investor communications — in that order of trust — before it reaches a caption.
"Insulin independence" and "cure" are not the same claim. We separate management, disease modification, functional cure, and durable cure — every time.
When a program's status changes, we say what we originally said, what changed, and why — labeled, not buried.